Sep 24, 2019 Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma Learn More
Sep 19, 2019 Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference Learn More
Sep 16, 2019 Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma Learn More
Sep 10, 2019 Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019 Learn More